Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition
Genetic Predisposition to Disease, Breast Cancer Female, Ovarian Cancer
About this trial
This is an interventional health services research trial for Genetic Predisposition to Disease focused on measuring NCCN guidelines, genetic testing, hereditary cancer, breast cancer, ovarian cancer, intervention, sequential intervention, message-based intervention, text message, diverse patient population, genetics, female, digital health technology, germline genetic testing, nudge, EHR based intervention, genetic counseling
Eligibility Criteria
Inclusion Criteria: Patients with serous ovarian cancer diagnosed more than two years prior to study contact Patients with breast cancer diagnosed at <50 years of age more than two years prior to study contact Patients with triple negative breast cancer diagnosed more than two years prior to study contact Unaffected individuals reporting a family history of ovarian cancer Unaffected individuals reporting a family history of male breast cancer Unaffected individuals reporting a family history of breast cancer <50 years Exclusion Criteria: 1. Patients who have previously received genetic counseling and/or testing
Sites / Locations
- Abramson Cancer Center of the University of Pennsylvania
Arms of the Study
Arm 1
Experimental
Sequential Communications
This sequential arm contains three types of communication to be employed following non-response to the previous type. The initial communication will be a direct message to the patient via the MyPennMedicine. The subsequent message will be sent as a text via the Way To Health app(lication). The final communication will be a nudge to the patient's physician which will send upon opening the patient's chart and will remain as a flag thereafter.